Taken together, mutations in MYD88, CD79B and TBL1XR1 affected 54% (20/37) of our cohort, suggesting that NFκB pathway deregulation is a driving mechanism in PCNSL tumorigenesis. This evidence concerns the gene CD79B and primary central nervous system lymphoma.